Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.

Autor:	Xu C; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Hou P; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Li X; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Xiao M; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Zhang Z; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Li Z; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.; School of Basic Medical Sciences, Hebei University, Baoding 07100, China., Xu J; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Liu G; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China., Tan Y; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.; School of Basic Medical Sciences, Hebei University, Baoding 07100, China.; Department of Pathology, Affiliated Hospital of Hebei University, Baoding 07100, China., Fang C; School of Clinical Medicine, Hebei University, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 07100, China.; Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.
Jazyk:	angličtina
Zdroj:	Cancer biology & medicine [Cancer Biol Med] 2024 May 06; Vol. 21 (5).
DOI:	10.20892/j.issn.2095-3941.2023.0510
Abstrakt:	Among central nervous system-associated malignancies, glioblastoma (GBM) is the most common and has the highest mortality rate. The high heterogeneity of GBM cell types and the complex tumor microenvironment frequently lead to tumor recurrence and sudden relapse in patients treated with temozolomide. In precision medicine, research on GBM treatment is increasingly focusing on molecular subtyping to precisely characterize the cellular and molecular heterogeneity, as well as the refractory nature of GBM toward therapy. Deep understanding of the different molecular expression patterns of GBM subtypes is critical. Researchers have recently proposed tetra fractional or tripartite methods for detecting GBM molecular subtypes. The various molecular subtypes of GBM show significant differences in gene expression patterns and biological behaviors. These subtypes also exhibit high plasticity in their regulatory pathways, oncogene expression, tumor microenvironment alterations, and differential responses to standard therapy. Herein, we summarize the current molecular typing scheme of GBM and the major molecular/genetic characteristics of each subtype. Furthermore, we review the mesenchymal transition mechanisms of GBM under various regulators. Competing Interests: No potential conflicts of interest are disclosed. (Copyright: © 2024, The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF